Spironolactone, an ingredient
of Aldactazide, has been shown to be a tumorigen in
chronic toxicity studies in rats (see PRECAUTIONS).
Aldactazide should be used only in those conditions
described under INDICATIONS AND USAGE.
Unnecessary use of this drug should be avoided.
Fixed-dose combination drugs are not indicated
for initial therapy of edema or hypertension. Edema
or hypertension requires therapy titrated to the
individual patient. If the fixed combination represents
the dosage so determined, its use may be more convenient
in patient management. The treatment of hypertension
and edema is not static but must be reevaluated
as conditions in each patient warrant.
|
